학술논문

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome
Document Type
Artikel
Source
Rheumatology (Oxford, England). 60(3):1364-1375
Subject
Medicin och hälsovetenskap
Language
English
English
ISSN
1462-0332